Economic evaluation of urethroplasty vs. repeated endoscopic dilation in short bulbar urethral stricture management
DOI:
https://doi.org/10.5489/cuaj.9460Keywords:
urethroplasty, dilation, stricture, bulbar, costAbstract
Introduction: Management of short bulbar urethral strictures (<2 cm) typically involves either endoscopic dilation or excision and primary anastomosis urethroplasty. While dilation is inexpensive and minimally invasive, it carries high recurrence rates. Urethroplasty is more durable but requires higher upfront resources. We conducted a decision analysis to compare the 10-year costs of both strategies.
Methods: A decision tree was constructed to model stricture recurrence and complications after either index procedure. Direct institutional costs were obtained from hospital financial data and the Quebec physician fee schedule, expressed in 2023 Canadian dollars. Ten-year cumulative costs were calculated with a 3% annual discount rate. One-way sensitivity analyses varied recurrence and complication rates across published ranges.
Results: The average cost of urethroplasty was $7186.27 CAD compared with $441.20 CAD for dilation. Stricture recurrence was 15.5% after urethroplasty vs. 60%, 80%, and 95% after first, second, and third dilations, respectively. Over 10 years, cumulative costs were $21 714.04 CAD for urethroplasty and $25 037.45 CAD for dilation, with a break-even point at approximately 80 months. Across sensitivity analyses, urethroplasty became more expensive with varying complication rates, but remained cost-efficient across a range of recurrence rates.
Conclusions: Despite higher initial expenses, urethroplasty is the more cost-efficient strategy for managing short bulbar urethral strictures. Given patients’ relatively young age at diagnosis, cost benefits are likely to accrue beyond 10 years, supporting urethroplasty as the preferred definitive approach after at most one dilation attempt.
Downloads
Downloads
Published
How to Cite
Issue
Section
License
You, the Author(s), assign your copyright in and to the Article to the Canadian Urological Association. This means that you may not, without the prior written permission of the CUA:
- Post the Article on any Web site
- Translate or authorize a translation of the Article
- Copy or otherwise reproduce the Article, in any format, beyond what is permitted under Canadian copyright law, or authorize others to do so
- Copy or otherwise reproduce portions of the Article, including tables and figures, beyond what is permitted under Canadian copyright law, or authorize others to do so.
The CUA encourages use for non-commercial educational purposes and will not unreasonably deny any such permission request.
You retain your moral rights in and to the Article. This means that the CUA may not assert its copyright in such a way that would negatively reflect on your reputation or your right to be associated with the Article.
The CUA also requires you to warrant the following:
- That you are the Author(s) and sole owner(s), that the Article is original and unpublished and that you have not previously assigned copyright or granted a licence to any other third party;
- That all individuals who have made a substantive contribution to the article are acknowledged;
- That the Article does not infringe any proprietary right of any third party and that you have received the permissions necessary to include the work of others in the Article; and
- That the Article does not libel or violate the privacy rights of any third party.







